Effect of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate

Gut

Volumn 53, Issue 12, 2004, Pages 1825-1831

  Sohn, K J ^b   Smirnakis, F ^a   Moskovitz, D N ^b   Novakovic, P ^b   Yates, Z ^c   Lucock, M ^c   Croxford, R ^d   Kim, Y I ^a,b,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLIC ACID DERIVATIVE; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; POLYGLUTAMIC ACID; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; PEPTIDE SYNTHASE;

ARTICLE; CHEMOSENSITIVITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH RATE; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; CELL CULTURE; CELL DIVISION; CELL SURVIVAL; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; METHOTREXATE; PEPTIDE SYNTHASES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 9344238265     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2004.042713     Document Type: Article

References (54)

1. Shane B. Folate chemistry and metabolism. In: Bailey LB, eds. Folate in health and disease. New York: Marcel Dekker, 1995:1-22.
2. Moran RG. Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 1999;26:24-32.
3. Kamen B. Folate and antifolate pharmacology. Semin Oncol 1997;24:S18-39.
4. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981;41:2751-6.
5. Jolivet J, Schilsky RL, Bailey BD, et al. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 1982;70:351-60.
6. Samuels LL, Moccio DM, Sirotnak FM. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro. Cancer Res 1985;45:1488-95.
7. Allegra CJ, Chabner BA, Drake JC, et al. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985;260:9720-6.
8. Allegra G, Hoang K, Yeh GC, et al. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 1987;262:13520-6.
9. Moran RG, Colman PD, Jones TR. Relative substrate activities of structurally related pteridine, quinazoline, and pyrimidine analogs for mouse liver folylpalyglutamate synthetase. Mol Pharmacol 1989;36:736-43.
10. Baldwin SW, Tse A, Gossett LS, et al. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry 1991;30:1997-2006.
11. Allegra CJ, Drake JC, Jolivet J, et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 1985;82:4881-5.
12. Pizzorno G, Mini E, Coronnello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988;48:2149-55.
13. McCloskey DE, McGuire JJ, Russell CA, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 1991;266:6181-7.
14. Mauritz R, Peters GJ, Priest DG, et al. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Biochem Pharmacol 2002;63:105-15.
15. Liani E, Rothem L, Bunni MA, et al. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-99.
16. Sanghani SP, Sanghani PC, Moran RG. Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-gamma- glutamate synthetase by site-directed mutagenesis. J Biol Chem 1999;274:27018-27.
17. Zhao R, Titus S, Gao F, et al. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofalate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000;275:26599-606.
18. Roy K, Egan MG, Sirlin S, et al. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in some folate analogue-resistant variants of the L1210 cell. Evidence for an altered cognate mRNA in the variants affecting the rate of de novo synthesis of the enzyme. J Biol Chem 1997;272:6903-8.
19. Kim JS, Lowe KE, Shane B. Regulation of folate and one-carbon metabolism in mammalian cells. IV. Rale of folylpoly-gamma-glutamate synthetase in methotrexate metabolism and cytotoxicity. J Biol Chem 1993;268:21680-5.
20. Aghi M, Kramm CM, Breakefieid XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in viva. J Natl Cancer Inst 1999;91:1233-41.
21. Longley DB, Harkin DP, Johnston PG, 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
22. Radparvar S, Haughton PJ, Houghton JA. Effect af polyglutamylatian of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′- deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989;38:335-42.
23. Romanini A, Lin JT, Niedzwiecki D, et al. Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 1991;51:789-93.
24. Wang FS, Aschele C, Sobrero A, et al. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res 1993;53:3677-80.
25. Cheradame S, Etienne MC, Chazal M, et al. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data. Eur J Cancer 1997;33:950-9.
26. Sahn KJ, Croxford R, Yates Z, et al. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 2004;96:134-44.
27. McGuire JJ, Russell CA. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines. Oncol Res 1998;10:193-200.
28. Peters GJ, Laurensse E, Leyva A, et al. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur J Cancer Clin Oncol 1987;23:1869-81.
29. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
30. O'Connor DL, Tamura T, Picciano MF. Pteroylpolyglutamates in human milk. Am J Clin Nutr 1991;53:930-4.
31. Yao R, Schneider E, Ryan TJ, et al. Human gamma-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro. Proc Natl Acad Sci U S A 1996;93:10134-8.
32. Cole PD, Kamen BA, Gorlick R, et al. Effects of overexpression of gamma-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 2001;61:4599-604.
33. Keepers YP, Pizao PE, Peters GJ, et al. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27:897-900.
34. Draper NR, Smith H. Applied regression analysis, 2nd Edn., New York: John Wiley & Sons 1981.
35. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003;54:437-52.
36. Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343-9.
37. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998;58:1149-58.
38. Paradiso A, Simone G, Petroni S, et al. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000;82:560-7.
39. Chazal M, Cheradame S, Formento JL, et al. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin Cancer Res 1997;3:553-7.
40. Mini E, Biondi C, Morganti M, et al. Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res 1999;11:437-45.
41. Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003;9:6012-9.
42. Kemeny N, Lokich JJ, Anderson N, et al. Recent advances in the treatment of advanced colarectal cancer. Cancer 1993;71:9-18.
43. Jansen G, Barr H, Kathmann I, et al. Multiple mechanisms of resistance to polyglutamatable and lipophilic antifolates in mammalian cells: role of increased folylpolyglutamylation, expanded folate pools, and intralysosomal drug sequestration. Mol Pharmacol 1999;55:761-9.
44. Jansen G, Mauritz R, Drori S, et al. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 1998;273:30189-98.
45. Tse A, Moran RG. Cellular folates prevent polyglutamation of 5, 10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J Biol Chem 1998;273:25944-52.
46. Peters GJ, Smitskamp-Wilms E, Smid K, et al. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res 1999;59:5529-35.
47. O'Dwyer PJ, Nelson K, Thornton DE. Overview of phase II trials of MTA in solid tumors. Semin Oncol 1999;26:99-104.
48. Ames BN. DNA damage from micronutrient deficiencies is likely ta be a major cause of cancer. Mutat Res 2001;475:7-20.
49. Fenech M. The role of folic acid and Vitamin B12 in genomic stability of human cells. Mutat Res 2001;475:57-67.
50. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
51. Fournel M, Sapieha P, Beaulieu N, et al. Down-regulation of human DNA-(cytosine-5) methyltransferase induces cell cycle regulators p16(ink4A) and p21(WAF/Cip1) by distinct mechanisms. J Biol Chem 1999;274:24250-6.
52. Grem JL. Fluorinated pyrimidines. In: Grem JL, Collins J, eds. Cancer chemotherapy: principles and practices. New York: J B Lippincott Company, 1990:180-224.
53. Backus HH, Pinedo HM, Wouters D, et al. Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 2000;87:771-8.
54. Preist DG, Bunni MA. Folates and folate antagonists in cancer chemotherapy. In: Bailey LB, eds. Folate in health and disease. New York: Marcel Dekker, 1995:379-403.